Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+44 1494 818 025

Testimonials
I could not speak more highly of Zenopa and my Account Manager. From the word go I found them to be fully professional and helpful keeping me updated all the way through the recruitment process and al...
Phil, 2013

Novo Nordisk reports positive data from Victoza analyses

27 November 2012 10:58 in Pharmaceutical Company Product News


Novo Nordisk has reported data from new studies that provide further evidence of the benefits of Victoza, its liraglutide-based therapy for type 2 diabetes.

Recent analyses have shown that the drug is able to deliver better rates of blood glucose reduction after 26 weeks of treatment than a pair of alternative therapy options.

A further study demonstrated that Victoza can also provide advantages when used as an add-on to metformin, thus helping patients to reduce their risk of complications associated with the disease.

The drug has been approved for use in Europe since 2009 and has been prescribed to more than half a million patients worldwide to date.

Dr Allen King from the Diabetes Care Centre in Salinas said: "We know that by achieving treatment goals sooner, outcomes are improved so it's important that effective treatments, such as liraglutide, are used early in the management of type 2 diabetes."

Last month, the company applied for European and US regulatory approval of turoctocog alfa, a new compound for use in the treatment of haemophilia A.ADNFCR-8000103-ID-801495437-ADNFCR

Other news stories from 27/11/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd